BRIEF published on 08/08/2024 at 07:35, 1 month 10 days ago Evotec Advances Neuroscience Partnership with Bristol Myers Squibb Partnership Research Neuroscience Evotec Bristol Myers Squibb
PRESS RELEASE published on 08/08/2024 at 07:30, 1 month 10 days ago Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb Evotec SE announces progress in strategic neuroscience partnership with Bristol Myers Squibb, receiving US$ 25 million payment for further research on neurodegenerative diseases Evotec SE Research Neurodegenerative Diseases Bristol Myers Squibb Neuroscience Partnership
BRIEF published on 08/07/2024 at 13:05, 1 month 11 days ago Evotec SE to Announce First Half-Year 2024 Results on 14 August 2024 Financial Results Conference Call Evotec SE Webcast First Half-year 2024
BRIEF published on 08/07/2024 at 13:05, 1 month 11 days ago Evotec SE annoncera ses résultats du premier semestre 2024 le 14 août 2024 Résultats Financiers Evotec SE Webdiffusion Conférence Téléphonique Premier Semestre 2024
PRESS RELEASE published on 08/07/2024 at 13:00, 1 month 11 days ago Evotec SE reports first half-year 2024 results on 14 August 2024 Evotec SE to report first half-year 2024 results on 14 August 2024. Conference call scheduled to discuss financial performance and updates. Webcast available on www.evotec.com/en/investor-relations/financial-publications Conference Call Financial Performance Evotec SE Webcast First Half-year Results
BRIEF published on 08/06/2024 at 21:12, 1 month 12 days ago Evotec Provides Updated Fiscal Guidance for 2024 Adjusted EBITDA Revenue Forecast Sustainable Growth 2024 Guidance Evotec
BRIEF published on 08/06/2024 at 21:12, 1 month 12 days ago Evotec fournit des orientations fiscales mises à jour pour 2024 EBITDA Ajusté Prévisions De Revenus Evotec Une Croissance Durable Orientation 2024
BRIEF published on 08/06/2024 at 21:09, 1 month 12 days ago Evotec SE met à jour ses prévisions financières pour 2024 Evotec SE EBITDA Ajusté Conseils Financiers Prévisions De Revenus Dépenses De R&D
BRIEF published on 08/06/2024 at 21:09, 1 month 12 days ago Evotec SE Updates Financial Guidance for 2024 Adjusted EBITDA Revenue Forecast Financial Guidance Evotec SE R&D Expenditure
PRESS RELEASE published on 08/06/2024 at 21:07, 1 month 12 days ago Evotec provides guidance update Evotec SE refines guidance for fiscal year 2024, expecting moderate revenue growth, reduced R&D expenditures, and adjusted EBITDA; aims for sustainable profitable growth amid market challenges Adjusted EBITDA Revenue Growth Evotec SE Guidance Update R&D Expenditures
Published on 09/18/2024 at 23:10, 4 hours 3 minutes ago Ur-Energy Provides Operations, Construction and 2024 Guidance Updates
Published on 09/18/2024 at 23:00, 4 hours 13 minutes ago Garden State Gold & Coin Applauds Passage of Historic NJ Sales Tax Bill on Precious Metals
Published on 09/18/2024 at 21:15, 5 hours 58 minutes ago New to the Street Launches 24-Part Series with ARAX Holdings, Spotlighting Core Blockchain, CorePass, Lunaº Mesh, and Revolutionary Tech Solutions
Published on 09/18/2024 at 21:00, 6 hours 13 minutes ago Falcon Commences Drilling At Its Great Burnt Copper Project, NL
Published on 09/18/2024 at 16:30, 10 hours 43 minutes ago Manimal Tales Launches New Nursery Rhyme Based Detective Series: Your Child Solves Nursery Crimes in our Newest Personalized Book!
Published on 09/18/2024 at 19:11, 8 hours 2 minutes ago EQS-Adhoc: alstria office REIT-AG: squeeze-out demand regarding the shares of minority shareholders, amendment to investment agreement, loss of REIT-status at year-end 2024
Published on 09/18/2024 at 18:45, 8 hours 28 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/18/2024 at 18:31, 8 hours 42 minutes ago EQS-Adhoc: Vonovia SE: Initiation of the process to conclude a domination and profit and loss transfer agreement between Vonovia SE and Deutsche Wohnen SE
Published on 09/18/2024 at 18:13, 9 hours ago BILENDI: Creating discussion guides for market research is now possible with AI, thanks to BARI and Bilendi Discuss
Published on 09/18/2024 at 17:21, 9 hours 51 minutes ago EQS-Adhoc: Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 154,053 no-par value bearer shares at an issue price of EUR 5 per share
Published on 09/18/2024 at 18:45, 8 hours 28 minutes ago Augmentation de capital consécutive à l'attribution gratuite d'actions aux salariés du groupe EuropaCorp
Published on 09/18/2024 at 18:45, 8 hours 28 minutes ago Capital increase following the allocation of free shares to EuropaCorp employees
Published on 09/18/2024 at 17:40, 9 hours 33 minutes ago Groupe CRIT : Modalités de mise à disposition du Rapport Financier semestriel 2024.